Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

9.710 USD -0.010 (-0.10%)
Streaming Delayed Price Updated: 7:55 AM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Inovio Pharma

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Report Second Quarter 2016 Financial Results August 8, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 second quarter financial results and provide a corporate update on... 
From GlobeNewswire News Releases
Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV
Funding for Potential Breakthrough Therapy is Part of Prestigious NIH/Delany Grant for Industry-Academic Collaboration 
From GlobeNewswire News Releases
Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
From PR Newswire
Inovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science, Inc. (KSE:011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA... 
From GlobeNewswire News Releases
These Companies Prove that Reverse Splits Can Be a Very Good Thing for Stakeholders
From ACCESSWIRE
Inovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates
Inovio will conduct human studies later this year 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Present at UBS Global Healthcare Conference
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported that the Company will present a corporate overview at the UBS Global Healthcare Conference on Wednesday, May 25th at 8:30AM EDT. 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2016 First Quarter Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2016. 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene & Cell Therapy
Worldwide Scientific Forum Selects Inovio’s Ebola Vaccine Challenge Results for its Presidential Symposium 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration 
From GlobeNewswire News Releases
Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial
DNA-based immunotherapy will be tested for safety and immune responses in quest to eliminate HCV infection 
From GlobeNewswire News Releases
Inovio Pharmaceuticals to Report First Quarter 2016 Financial Results May 9, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 8:30 a.m.... 
From GlobeNewswire News Releases
Inovio Ebola Vaccine Generates Robust Immune Responses in Humans
Human immunogenicity data combined with efficacy in multiple animal species warrants further human study 
From GlobeNewswire News Releases
Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its immunotherapy to treat cervical dysplasia (VGX-3100) was recognized as "Best Therapeutic Vaccine" by the World Vaccine Congress held... 
From GlobeNewswire News Releases
Inovio Updates INO-3112 HPV Immunotherapy Development Plan
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical strategy update to take its INO-3112 HPV immunotherapy into human studies in combination with selected immunotherapy molecules from... 
From GlobeNewswire News Releases
Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
Ability of unique dMAb and DNA vaccine combination to induce rapid short-term and long-term protection has broad implications for infectious disease prevention and control 
From GlobeNewswire News Releases
Biotechs in the News
Tags Banking & Financial Services
From ACCESSWIRE
Covered Call Alerts For Marathon Oil Corporation, Amazon.com, Chesapeake Energy, ConocoPhillips and Inovio Pharmaceuticals Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for MRO, AMZN, CHK, COP and INO. 
From PR Newswire
Inovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and Vaccines
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed collaborative research agreements (CRAs) with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy... 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines
Non-invasive integrated injection and electroporation device to enhance mass immunization against flu, RSV, and pandemic/tropical infectious diseases using transformative immune-activating technology 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2015. 
From GlobeNewswire News Releases
Inovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer David B. Weiner, Ph.D., to its Board of Directors
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that David B. Weiner, Ph.D., recognized in scientific circles as the “father of DNA vaccines and immunotherapies,” has been appointed to... 
From GlobeNewswire News Releases
Covered Call Alerts For Bank of America, Twitter, Inovio Pharmaceuticals, Marathon Oil Corporation and Amicus Therapeutics Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for BAC, TWTR, INO, MRO and FOLD. 
From PR Newswire
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2015 Financial Results on March 14, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2015 fourth quarter and year-end financial results on Monday, March 14, 2016... 
From GlobeNewswire News Releases
Covered Call Alerts For Freeport-McMoRan, Inovio Pharmaceuticals, Chevron, NVIDIA and Groupon Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for FCX, INO, CVX, NVDA and GRPN. 
From PR Newswire
Inovio Pharmaceutical's DNA Vaccine for Zika Virus Induces Robust Immune Responses in Preclinical Study
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential... 
From GlobeNewswire News Releases
Early Briefing on Biotechnology Stocks -- Achillion Pharma, CTI BioPharma, Inovio Pharma, and Keryx Biopharma
Tags Publishing & Media
From ACCESSWIRE
Inovio Pharmaceuticals Inc. (NASDAQ: INO) Working on a Zika Vaccine
Tags Banking & Financial Services
From ACCESSWIRE
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
Tags Business & Professional Services
From ACCESSWIRE
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.